March 15, 2013
Athens, GA – Abeome Corporation announced today the receipt of an award letter for a Small Business Innovative Research (SBIR) grant in the amount of $275,916 over 10 months. The grant, titled “Semi-Targeted Immunotherapeutic Approach for Treatment of Obesity,” is a Phase 1 grant focused on generating a large number of monoclonal antibodies to human preadipocytes, the cells that are the precursors to fat cells.
“We are very pleased that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) recognizes the value of our novel approach to rapid monoclonal antibody generation in obesity research, which has the potential to identify new intervention points in the progression to obesity and diabetes,” stated Dr. Richard A. Shimkets, President and CEO of Abeome Corporation.
About the Grant: The grant provides for the generation of a large collection of novel monoclonal antibodies, made using Abeome’s proprietary technology, that bind to human visceral preadipocyte cells. Antibodies will be tested for their ability to prevent preadipocytes from becoming fat-absorbing adipocytes in cell culture
About Monoclonal Antibodies: The annual market for monoclonal antibodies for use as therapeutics, diagnostics, and research reagents is over $50 billion, yet traditional technology typically generates 20 or fewer useful antibodies from a mouse. Accessing the full immune repertoire of the mouse enables the selection of antibodies with very specific and superior properties that are statistically impossible to obtain with traditional technology.
About Obesity: In the United States, 35.7% of adults are obese. Obesity-related conditions include heart disease, stroke, type 2 diabetes and certain types of cancer, which are some of the leading causes of preventable death. The annual medical costs associated with obesity in the US have been estimated to be about $150 billion (see http://www.cdc.gov/obesity/data/adult.html).
About Abeome: Abeome is a privately-held antibody discovery company focused on the high throughput selection, analysis and synthesis of monoclonal antibodies with a primary objective to develop best-in-class prescription products for the therapeutic antibody market – the fastest growing segment of global drug sales. For more information, please visit www.abeomecorp.com
AbeoMouse™and DiSH™, are registered trademarks of Abeome Corporation.